Breakthrough in Parkinson's Treatment: Adaptive Deep Brain Stimulation

Parkinson's disease, a progressive movement disorder affecting approximately 1.1 million Americans and 10 million people globally, is characterized by symptoms such as tremors, stiffness, and balance issues. Keith Krehbiel, a Stanford University professor diagnosed with early onset Parkinson's in 1997, exemplifies the challenges faced by patients. Initially dismissing his symptoms, Krehbiel's condition deteriorated over the years, leading to increased falls and cognitive difficulties. He described living with Parkinson's as a struggle with a "brain fog" and constant nausea.

CNN

Krehbiel became the first participant in a pivotal international clinical trial for an adaptive deep brain stimulation (aDBS) device, which functions similarly to a pacemaker for the brain. Unlike traditional deep brain stimulation, which delivers constant electrical pulses, the aDBS device adjusts stimulation based on real-time brain activity. Dr. Helen Bronte-Stewart, a Stanford neurologist and the trial's global lead investigator, emphasized that this innovation represents a significant advancement in Parkinson's treatment, offering a more tailored approach to managing symptoms.

CNN

The aDBS device, developed by Medtronic, received FDA approval in February 2025, marking a milestone in Parkinson's treatment. Bronte-Stewart noted that the device's adaptive technology is a major improvement over previous methods, which were often ineffective for many patients. Krehbiel's experience with the device has been transformative; since its implantation in 2020, he has experienced a significant reduction in hand tremors and has been able to decrease his reliance on medications that caused grogginess.

CNN

While the aDBS device does not cure Parkinson's, it is described as a "wonderful, stable, long-term therapy" that may slow disease progression. Krehbiel reported feeling cognitively clearer and more physically capable, stating, “It sure makes life better in the sense of alleviating some of the nasty part of Parkinson’s.” He acknowledged that while challenges remain, the device has improved his quality of life significantly.

CNN

Despite the advancements, some experts caution that the aDBS device is not a panacea. Bronte-Stewart acknowledged that while the technology is promising, ongoing research is necessary to enhance its effectiveness and address the complexities of Parkinson's disease. Critics emphasize the need for continued innovation and patient-centered approaches in treatment.

CNN

• “I thought, well, if you’re going to be cursed with something,” — Keith Krehbiel, Parkinson's Patient

CNN

• “There’s a lot more to do, but certainly the beginning is very exciting.” — Dr. Helen Bronte-Stewart, Neurologist

CNN

• “then people really do [improve]. What they say is their disease goes back at least five years.” — Dr. Helen Bronte-Stewart, Neurologist

CNN

The development of the aDBS device represents a significant step forward in the treatment of Parkinson's disease, offering hope to patients like Krehbiel and potentially transforming the landscape of neurological care.

CNN